Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis.
暂无分享,去创建一个
Stefan Michiels | Benjamin Haibe-Kains | Christine Desmedt | Christos Sotiriou | Fabrice Andre | Sherene Loi | C. Sotiriou | S. Loi | B. Haibe-Kains | C. Desmedt | M. Piccart | S. Michiels | C. Criscitiello | F. André | M. Ignatiadis | S. Singhal | Martine Piccart | Carmen Criscitiello | Michail Ignatiadis | Sandeep K Singhal
[1] I. Ellis,et al. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer , 2007, Genome Biology.
[2] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .
[3] J. Haerting,et al. Gene-expression signatures in breast cancer. , 2003, The New England journal of medicine.
[4] C. Denkert,et al. Effect of neoadjuvant anthracycline–taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study , 2010, Breast Cancer Research and Treatment.
[5] S. Paik,et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Yuan Qi,et al. Evaluation of a 30-Gene Paclitaxel, Fluorouracil, Doxorubicin, and Cyclophosphamide Chemotherapy Response Predictor in a Multicenter Randomized Trial in Breast Cancer , 2010, Clinical Cancer Research.
[7] David Cameron,et al. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer , 2009, Nature Medicine.
[8] Melissa L. Johnson,et al. Emerging targeted therapies for breast cancer. , 2007, Hematology/oncology clinics of North America.
[9] Christos Hatzis,et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] A. Nobel,et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] G. Hortobagyi,et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Jung-Sik Kim,et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors , 2009, EMBO molecular medicine.
[13] Yuan Qi,et al. Multifactorial approach to predicting resistance to anthracyclines. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] A. Chinnaiyan,et al. Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. , 2006, Cancer research.
[15] J. Baselga,et al. A phase I study of the oral mTOR inhibitor ridaforolimus (RIDA) in combination with the IGF-1R antibody dalotozumab (DALO) in patients (pts) with advanced solid tumors. , 2010 .
[16] D. Berry,et al. I‐SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy , 2009, Clinical pharmacology and therapeutics.
[17] C. Sotiriou,et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures , 2007, Breast Cancer Research.
[18] Z. Szallasi,et al. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers , 2006, Nature Genetics.
[19] Jeffrey T. Chang,et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies , 2006, Nature.
[20] J. Ferlay,et al. Estimates of the cancer incidence and mortality in Europe in 2006. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] Liao Ning,et al. Nomograms to Predict Pathologic Complete Response and Metastasis-Free Survival after Preoperative Chemotherapy for Breast Cancer , 2007 .
[22] Sunil J Rao,et al. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis , 2003 .
[23] Xavier Robin,et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves , 2011, BMC Bioinformatics.
[24] M. Pencina,et al. Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.
[25] A. Chinnaiyan,et al. Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. , 2006, Cancer research.
[26] G. Bonadonna,et al. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] Tanja Cufer,et al. TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. , 2011, The Lancet. Oncology.
[28] M. J. van de Vijver,et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. , 2006, Journal of the National Cancer Institute.
[29] Laurence Zitvogel,et al. Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy , 2007, Nature Medicine.
[30] Annuska M. Glas,et al. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer , 2010, Breast Cancer Research and Treatment.
[31] C. Sotiriou,et al. Genomic grade index is associated with response to chemotherapy in patients with breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] R. Schreiber,et al. Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.
[33] J. Ferlay,et al. Estimates of cancer incidence and mortality in Europe in 2008. , 2010, European journal of cancer.
[34] Johan Staaf,et al. Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] Z. Szallasi,et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] Philip M. Long,et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[37] Andreas Makris,et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] T. Golub,et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways , 2004, Nature Medicine.
[39] M. Ringnér,et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity , 2007, Proceedings of the National Academy of Sciences.
[40] Paul Ellis,et al. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor–positive breast cancer , 2010, Proceedings of the National Academy of Sciences.
[41] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[42] Stefan Michiels,et al. Gene expression profiling: does it add predictive accuracy to clinical characteristics in cancer prognosis? , 2007, European journal of cancer.
[43] Roman Rouzier,et al. Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy , 2005, Clinical Cancer Research.
[44] R. Gelber,et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial , 2012, The Lancet.
[45] L. Zitvogel,et al. The anticancer immune response: indispensable for therapeutic success? , 2008, The Journal of clinical investigation.
[46] K. Hess,et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] M. Cronin,et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.
[48] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[49] Roman Rouzier,et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] Adrian V. Lee,et al. Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] D. Moher,et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement , 2009, BMJ.
[52] Carsten Denkert,et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] Alan Ashworth,et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.
[54] J. Trimarchi,et al. E2f3 is critical for normal cellular proliferation. , 2000, Genes & development.
[55] Gianluca Bontempi,et al. Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes , 2008, Clinical Cancer Research.
[56] D. Moher,et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement , 2009, BMJ : British Medical Journal.
[57] Yuan Qi,et al. Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. , 2011, Journal of the National Cancer Institute.
[58] L. Esserman,et al. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. , 2011, JAMA.
[59] Yudong D. He,et al. Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.
[60] Maqc Consortium. The MicroArray Quality Control ( MAQC )-II study of common practices for the development and validation of microarray-based predictive models , 2012 .